Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Using Genetics to Evaluate the Success of a Feral Cat (Felis catus) Control Program in North-Western Australia.

Cowen S, Clausen L, Algar D, Comer S.

Animals (Basel). 2019 Dec 1;9(12). pii: E1050. doi: 10.3390/ani9121050.

2.

Naloxone-Induced Withdrawal in Individuals With and Without Fentanyl-Positive Urine Samples.

Jones JD, Sherwin E, Martinez S, Comer SD.

Am J Addict. 2019 Nov 29. doi: 10.1111/ajad.12979. [Epub ahead of print]

PMID:
31782591
3.

Changes in cardiac vagal tone as measured by heart rate variability during naloxone-induced opioid withdrawal.

Levin CJ, Wai JM, Jones JD, Comer SD.

Drug Alcohol Depend. 2019 Nov 1;204:107538. doi: 10.1016/j.drugalcdep.2019.06.040. Epub 2019 Sep 3.

PMID:
31513980
4.

Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone.

Jones JD, Mumtaz M, Manubay JM, Mogali S, Sherwin E, Martinez S, Comer SD.

Pharmacol Biochem Behav. 2019 Nov;186:172778. doi: 10.1016/j.pbb.2019.172778. Epub 2019 Sep 4.

PMID:
31493434
5.

A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.

Jones JD, Babalonis S, Marcus R, Vince B, Kelsh D, Lofwall MR, Fraser H, Paterson B, Martinez S, Martinez DM, Nunes EV, Walsh SL, Comer SD.

Addict Biol. 2019 Jun 26:e12799. doi: 10.1111/adb.12799. [Epub ahead of print]

PMID:
31240842
6.

Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Pravetoni M, Comer SD.

Neuropharmacology. 2019 Nov 1;158:107662. doi: 10.1016/j.neuropharm.2019.06.001. Epub 2019 Jun 4. Review.

PMID:
31173759
7.

Medical Devices to Prevent Opioid Use Disorder: Innovative Approaches to Addressing the Opioid Crisis.

Comer SD, Dworkin RH, Strain EC.

JAMA Psychiatry. 2019 Apr 1;76(4):351-352. doi: 10.1001/jamapsychiatry.2018.4379. No abstract available.

PMID:
30785611
8.

Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.

Comer SD, Cahill CM.

Neurosci Biobehav Rev. 2019 Nov;106:49-57. doi: 10.1016/j.neubiorev.2018.12.005. Epub 2018 Dec 5. Review.

PMID:
30528374
9.

How competent are people who use opioids at responding to overdoses? Qualitative analyses of actions and decisions taken during overdose emergencies.

Neale J, Brown C, Campbell ANC, Jones JD, Metz VE, Strang J, Comer SD.

Addiction. 2019 Apr;114(4):708-718. doi: 10.1111/add.14510. Epub 2018 Dec 28.

PMID:
30476356
10.

Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse.

Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, Foltin RW, Haney M.

Addict Biol. 2019 Jul;24(4):765-776. doi: 10.1111/adb.12664. Epub 2018 Oct 31.

PMID:
30378231
11.

Fluorescence Multiplexing with Spectral Imaging and Combinatorics.

Holzapfel HY, Stern AD, Bouhaddou M, Anglin CM, Putur D, Comer S, Birtwistle MR.

ACS Comb Sci. 2018 Nov 12;20(11):653-659. doi: 10.1021/acscombsci.8b00101. Epub 2018 Oct 30.

PMID:
30339749
12.

The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety.

Jones JD, Bisaga A, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, Madera G, Doernberg M, Comer SD.

J Psychoactive Drugs. 2018 Nov-Dec;50(5):390-401. doi: 10.1080/02791072.2018.1508789. Epub 2018 Sep 11.

13.

Analysis of Protein Phosphorylation Using Phos-Tag Gels.

Nagy Z, Comer S, Smolenski A.

Curr Protoc Protein Sci. 2018 Aug;93(1):e64. doi: 10.1002/cpps.64. Epub 2018 Jul 25.

PMID:
30044546
14.

The women's heart health programme: a pilot trial of sex-specific cardiovascular management.

Low TT, Chan SP, Wai SH, Ang Z, Kyu K, Lee KY, Ching A, Comer S, Tan NQP, Thong EGHE, Nang T, Dutta M, Lam CSP.

BMC Womens Health. 2018 Apr 16;18(1):56. doi: 10.1186/s12905-018-0548-6.

15.

Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers.

Haney M, Cooper ZD, Bedi G, Herrmann E, Comer SD, Reed SC, Foltin RW, Levin FR.

Addict Biol. 2019 Jul;24(4):707-716. doi: 10.1111/adb.12621. Epub 2018 Apr 16.

PMID:
29659126
16.

Evaluating the efficacy of a landscape scale feral cat control program using camera traps and occupancy models.

Comer S, Speldewinde P, Tiller C, Clausen L, Pinder J, Cowen S, Algar D.

Sci Rep. 2018 Mar 28;8(1):5335. doi: 10.1038/s41598-018-23495-z.

17.

Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability.

Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M.

Neuropsychopharmacology. 2018 Sep;43(10):2046-2055. doi: 10.1038/s41386-018-0011-2. Epub 2018 Feb 5.

18.

Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse.

Raleigh MD, Peterson SJ, Laudenbach M, Baruffaldi F, Carroll FI, Comer SD, Navarro HA, Langston TL, Runyon SP, Winston S, Pravetoni M, Pentel PR.

PLoS One. 2017 Dec 1;12(12):e0184876. doi: 10.1371/journal.pone.0184876. eCollection 2017.

19.

Chronic pain and opioid abuse: Factors associated with health-related quality of life.

Jones JD, Vogelman JS, Luba R, Mumtaz M, Comer SD.

Am J Addict. 2017 Dec;26(8):815-821. doi: 10.1111/ajad.12637. Epub 2017 Nov 21.

20.

Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential.

Jones JD, Comer SD, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, Martinez S, Mumtaz M, Bisaga A.

Pharmacol Biochem Behav. 2017 Dec;163:90-100. doi: 10.1016/j.pbb.2017.10.002. Epub 2017 Oct 8.

21.

Glial and neuroinflammatory targets for treating substance use disorders.

Bachtell RK, Jones JD, Heinzerling KG, Beardsley PM, Comer SD.

Drug Alcohol Depend. 2017 Nov 1;180:156-170. doi: 10.1016/j.drugalcdep.2017.08.003. Epub 2017 Aug 31. Review.

22.

Addiction as a brain disease does not promote injustice.

Bedi G, Martinez D, Levin FR, Comer S, Haney M.

Nat Hum Behav. 2017 Sep;1(9):610. doi: 10.1038/s41562-017-0203-5. No abstract available.

PMID:
31024150
23.

Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount.

Jones JD, Manubay JM, Mogali S, Metz VE, Madera G, Martinez S, Mumtaz M, Comer SD.

Drug Alcohol Depend. 2017 Oct 1;179:362-369. doi: 10.1016/j.drugalcdep.2017.06.033. Epub 2017 Jul 26.

PMID:
28844013
24.

Effects of ibudilast on oxycodone-induced analgesia and subjective effects in opioid-dependent volunteers.

Cooper ZD, Johnson KW, Vosburg SK, Sullivan MA, Manubay J, Martinez D, Jones JD, Saccone PA, Comer SD.

Drug Alcohol Depend. 2017 Sep 1;178:340-347. doi: 10.1016/j.drugalcdep.2017.04.029. Epub 2017 Jun 17.

PMID:
28688296
25.

Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.

Walsh SL, Comer SD, Lofwall MR, Vince B, Levy-Cooperman N, Kelsh D, Coe MA, Jones JD, Nuzzo PA, Tiberg F, Sheldon B, Kim S.

JAMA Psychiatry. 2017 Sep 1;74(9):894-902. doi: 10.1001/jamapsychiatry.2017.1874.

26.

Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations.

Smith SM, Jones JK, Katz NP, Roland CL, Setnik B, Trudeau JJ, Wright S, Burke LB, Comer SD, Dart RC, Dionne R, Haddox JD, Jaffe JH, Kopecky EA, Martell BA, Montoya ID, Stanton M, Wasan AD, Turk DC, Dworkin RH.

J Pain. 2017 Nov;18(11):1287-1294. doi: 10.1016/j.jpain.2017.03.015. Epub 2017 May 4.

27.

Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence.

Metz VE, Jones JD, Manubay J, Sullivan MA, Mogali S, Segoshi A, Madera G, Johnson KW, Comer SD.

Neuropsychopharmacology. 2017 Aug;42(9):1825-1832. doi: 10.1038/npp.2017.70. Epub 2017 Apr 10.

28.

Health Meanings among Foreign Domestic Workers in Singapore: A Culture-Centered Approach.

Dutta MJ, Comer S, Teo D, Luk P, Lee M, Zapata D, Krishnaswamy A, Kaur S.

Health Commun. 2018 May;33(5):643-652. doi: 10.1080/10410236.2017.1292576. Epub 2017 Mar 29.

PMID:
28353364
29.

No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone.

Jones JD, Campbell A, Metz VE, Comer SD.

Addict Behav. 2017 Aug;71:104-106. doi: 10.1016/j.addbeh.2017.03.008. Epub 2017 Mar 9.

30.

Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats.

Neelakantan H, Holliday ED, Fox RG, Stutz SJ, Comer SD, Haney M, Anastasio NC, Moeller FG, Cunningham KA.

ACS Chem Neurosci. 2017 May 17;8(5):1065-1073. doi: 10.1021/acschemneuro.6b00413. Epub 2017 Feb 13.

31.

Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder.

Metz VE, Sullivan MA, Jones JD, Evans E, Luba R, Vogelman J, Comer SD.

J Psychoactive Drugs. 2017 Jan-Mar;49(1):59-68. doi: 10.1080/02791072.2016.1259518. Epub 2016 Dec 5.

32.

Can Naloxone Be Used to Treat Synthetic Cannabinoid Overdose?

Jones JD, Nolan ML, Daver R, Comer SD, Paone D.

Biol Psychiatry. 2017 Apr 1;81(7):e51-e52. doi: 10.1016/j.biopsych.2016.08.013. Epub 2016 Aug 18. No abstract available.

33.

Do As I Say: Using Communication Role-Plays to Assess Sexual Assertiveness Following an Intervention.

Mercer Kollar LM, Davis TL, Monahan JL, Samp JA, Coles VB, Bradley EL, Sales JM, Comer SK, Worley T, Rose E, DiClemente RJ.

Health Educ Behav. 2016 Dec;43(6):691-698. Epub 2016 May 10.

34.

Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.

Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, Foltin RW, Haney M.

Psychopharmacology (Berl). 2016 Jul;233(13):2469-78. doi: 10.1007/s00213-016-4298-6. Epub 2016 Apr 16.

35.

The effects of heroin administration and drug cues on impulsivity.

Jones JD, Vadhan NP, Luba RR, Comer SD.

J Clin Exp Neuropsychol. 2016 Aug;38(6):709-20. doi: 10.1080/13803395.2016.1156652. Epub 2016 Apr 10.

36.

Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.

Jones JD, Luba RR, Vogelman JL, Comer SD.

Am J Addict. 2016 Jan;25(1):41-8. doi: 10.1111/ajad.12316. Epub 2015 Dec 21.

37.

Crystal chemistry of hydrothermally grown ternary alkali rare earth fluorides.

McMillen CD, Comer S, Fulle K, Sanjeewa LD, Kolis JW.

Acta Crystallogr B Struct Sci Cryst Eng Mater. 2015 Dec 1;71(Pt 6):768-76. doi: 10.1107/S2052520615017916. Epub 2015 Dec 1.

PMID:
26634734
38.

Hydrothermal Formation of Calcium Copper Tetrasilicate.

Johnson-McDaniel D, Comer S, Kolis JW, Salguero TT.

Chemistry. 2015 Dec 1;21(49):17560-4. doi: 10.1002/chem.201503364. Epub 2015 Oct 20.

PMID:
26482329
39.

The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users.

Jones JD, Sullivan MA, Manubay JM, Mogali S, Metz VE, Ciccocioppo R, Comer SD.

Physiol Behav. 2016 May 15;159:33-9. doi: 10.1016/j.physbeh.2015.10.006. Epub 2015 Oct 9.

40.

Inflammatory Pain Promotes Increased Opioid Self-Administration: Role of Dysregulated Ventral Tegmental Area μ Opioid Receptors.

Hipólito L, Wilson-Poe A, Campos-Jurado Y, Zhong E, Gonzalez-Romero J, Virag L, Whittington R, Comer SD, Carlton SM, Walker BM, Bruchas MR, Morón JA.

J Neurosci. 2015 Sep 2;35(35):12217-31. doi: 10.1523/JNEUROSCI.1053-15.2015.

41.

Need and utility of a polyethylene glycol marker to ensure against urine falsification among heroin users.

Jones JD, Atchison JJ, Madera G, Metz VE, Comer SD.

Drug Alcohol Depend. 2015 Aug 1;153:201-6. doi: 10.1016/j.drugalcdep.2015.05.021. Epub 2015 May 27.

42.

The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers.

Cooper ZD, Johnson KW, Pavlicova M, Glass A, Vosburg SK, Sullivan MA, Manubay JM, Martinez DM, Jones JD, Saccone PA, Comer SD.

Addict Biol. 2016 Jul;21(4):895-903. doi: 10.1111/adb.12261. Epub 2015 May 14.

43.

A review of pharmacogenetic studies of substance-related disorders.

Jones JD, Comer SD.

Drug Alcohol Depend. 2015 Jul 1;152:1-14. doi: 10.1016/j.drugalcdep.2015.03.003. Epub 2015 Mar 18. Review.

44.

The pharmacogenetics of alcohol use disorder.

Jones JD, Comer SD, Kranzler HR.

Alcohol Clin Exp Res. 2015 Mar;39(3):391-402. doi: 10.1111/acer.12643. Epub 2015 Feb 19. Review.

45.

Sex differences among opioid-abusing patients with chronic pain in a clinical trial.

Manubay J, Davidson J, Vosburg S, Jones J, Comer S, Sullivan M.

J Addict Med. 2015 Jan-Feb;9(1):46-52. doi: 10.1097/ADM.0000000000000086.

46.

Butyrylcholinesterase levels and subjective effects of smoked cocaine in healthy cocaine users.

Askalsky P, Kalapatapu RK, Foltin RW, Comer SD.

Am J Drug Alcohol Abuse. 2015 Mar;41(2):161-5. doi: 10.3109/00952990.2014.966197. Epub 2014 Oct 16.

47.

Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Greenwald MK, Comer SD, Fiellin DA.

Drug Alcohol Depend. 2014 Nov 1;144:1-11. doi: 10.1016/j.drugalcdep.2014.07.035. Epub 2014 Aug 19. Review.

48.

Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.

Jones JD, Sullivan MA, Vosburg SK, Manubay JM, Mogali S, Metz V, Comer SD.

Addict Biol. 2015 Jul;20(4):784-98. doi: 10.1111/adb.12163. Epub 2014 Jul 25.

49.

Characteristics and quality of life of opioid-dependent pregnant women in Austria.

Metz VE, Comer SD, Wuerzl J, Pribasnig A, Fischer G.

Arch Womens Ment Health. 2014 Dec;17(6):529-39. doi: 10.1007/s00737-014-0443-6. Epub 2014 Jul 15.

50.

The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.

Jones JD, Madera G, Comer SD.

Pharmacol Biochem Behav. 2014 Jul;122:299-306. doi: 10.1016/j.pbb.2014.04.012. Epub 2014 May 2.

Supplemental Content

Support Center